You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The company, which changed its name from Premaitha Health last month, saw a 73 percent increase in testing volumes during the first half of fiscal year 2018.
Quest Diagnostics and Oxford Immunotec Global announced this week that Quest has completed its previously announced acquisition of Oxford Immunotec's US laboratory services business.
Quest Diagnostics this week announced it is acquiring the outreach laboratory services of Marin General Hospital located in Greenbrae, California.
Guardant Health said this week that it closed an initial public offering of approximately 14.4 million shares of its common stock at $19 per share, raising gross proceeds of about $273.1 million.
The placing and subscription shares that are part of the offering are expected to start trading on the AIM market of the London Stock Exchange later this month.
The company plans to use parts of the proceeds from the offering to pay for the recent settlement with Illumina.
By early 2020, the UK company plans to develop a version of its Iona test that uses Illumina's sequencing technology.
Under the agreement, the companies plan to develop a customized solution that can be widely deployed for DNA sequencing.
Color announced it's offer $50 confirmatory testing for individuals who have positive results from 23andMe’s direct-to-consumer genetic test that gauges three BRCA1 and BRCA2 mutations
The UK-based noninvasive prenatal testing firm also said that it has raised £2.5 million in funding through a share subscription.